市場調査レポート
商品コード
1374825
野兎病治療の世界市場-2023年~2030年Global Tularemia Treatment Market -2023-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
野兎病治療の世界市場-2023年~2030年 |
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
|
世界の野兎病治療市場は、そのダイナミクスに影響を与える様々な要因によって、長年にわたって著しい成長と変貌を遂げてきました。グラム陰性の好気性多形桿菌であるFrancisella tularensisは、急性、肉芽腫性、発熱性、感染性の人獣共通感染症である野兎病を引き起こします。最も感染力の強い細菌種のひとつがF. tularensisです。
野兎病患者の最大20%が発疹を経験し、発疹は斑状、しみ状または斑状丘疹状に始まり、膿疱性に変化します。多形紅斑や結節性紅斑はまれです。
特に発展途上国における政府投資と研究開発が、腺性野兎病に対するドキシサイクリンやストレプトマイシンなどの新規治療に対する先進製品の利用を引き続き促進し、世界の野兎病治療市場を押し上げるであろう。
新興経済諸国は、高額の投資、所得水準、インフラ整備に牽引され、医療分野の改善において急速な成長を遂げています。いくつかの国では、研究の高まりにより、野兎病治療に対する大きな需要が発生しています。様々な国での技術進歩に伴う様々な共同研究、買収、ライセンス契約は、市場の成長を促進する重要な要因です。
2022年2月17日、国防科学技術研究所(Dstl)の研究開発者は、尿路感染症治療用に開発された抗生物質がペストやメリオイドーシスを含む幅広い疾患に有効であることを実証しました。この研究は、国防脅威削減局(DTRA)と産学が共同で行ったものです。抗生物質フィナフロキサシンはメルライオン社が製造している尿路感染症治療薬ですが、比較薬と比較すると、その明確な作用機序により活性が向上しています。マウス感染モデルにおいて、フィナフロキサシンは吸入性野兎病とペストを効果的に治療します。
さらに、2021年6月25日、世界の製薬企業であるヒクマ・ファーマシューティカルズPLCは、米国子会社であるヒクマ・ファーマシューティカルズUSA社を通じて、ドキシサイクリン注、USP、100mgを米国で発売しました。ドキシサイクリン注射液と呼ばれる抗生物質は、感受性の高い細菌によって引き起こされることが確実であるか、または強く信じられている感染症の治療に使用されます。
さらに、野兎病治療のための新しい医薬品やソリューションの利用が増加しています。腺性野兎病患者の増加と革新的な製品開発のための研究とともに複数の薬剤の利用の増加は、野兎病治療市場の成長を促進する主な要因であろう。
10人に1人がこれらのドキシサイクリンの副作用を頻繁に経験しています。頭痛、気分が悪くなる(嘔吐)、吐き気、日光過敏症などが副作用の例です。重篤な副作用は血液の問題を示すことがあり、鼻血、のどの痛み、発熱、倦怠感や一般的な体調不良など、説明のつかない出血やあざが含まれます。
具体的には、血便や粘液を伴う下痢、耳鳴りや腹痛。嚥下障害や痛み、喉の不快感、酸の逆流、食欲の低下、食事中に悪化する胸の痛みなどが挙げられます。
The global tularemia treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Francisella tularensis, a gram-negative, aerobic, pleomorphic bacillus, causes tularemia, an acute, granulomatous, febrile, infectious zoonosis. One of the most contagious bacterial species is F. tularensis.
Up to 20% of tularemia patients experience a rash that might start as macular, blotchy, or maculopapular before developing into pustular in nature. Erythema multiforme and erythema nodosum are uncommon.
Government investments and research, particularly in developing economies, will continue to drive utilization of advanced products for novel treatments such as doxycycline or streptomycin for glandular tularemia and boost the global tularemia treatment market.
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for tularemia treatment owing to the rising research. Various collaborations, acquisitions and license agreement with technological advancements among different countries will be a crucial factor driving the growth of the market.
On February 17, 2022, researchers at Defence Science and Technology Laboratory (Dstl) have demonstrated that an antibiotic developed for the treatment of urinary tract infections is effective at treating a wide range of diseases, including plague and melioidosis. This work was done in collaboration with industry, academia, along with the Defence Threat Reduction Agency (DTRA). The antibiotic finafloxacin is being manufactured by MerLion Pharmaceuticals to treat urinary tract infections, but when compared to comparator drugs, its distinct mode of action has improved activity. In mouse infection models, finafloxacin effectively treats inhalational tularemia and plague.
Additionally, on June 25, 2021, through its American subsidiary, Hikma Pharmaceuticals USA Inc., the worldwide pharmaceutical business Hikma Pharmaceuticals PLC has introduced Doxycycline Injection, USP, 100mg, in the US. An antibiotic called doxycycline injection is used for the treatment of infections that are definitely or highly believed to be brought on by bacteria that are sensitive.
Furthermore, the rising utilization of novel medicines and solutions for tularemia treatment. Rising glandular tularemia cases and increasing utilization of several drugs along with research for innovative product development will be a major factor driving the growth of the tularemia treatment market.
One in ten persons experience these doxycycline side effects often. Headaches, feeling ill (vomiting), nausea, and sun sensitivity are examples of side effects. Serious side effects can indicate blood issues and include bleeding or bruises that cannot be explained, including nosebleeds, a sore throat, a fever, and feeling weary or generally ill.
Diarrhea that is bloody or mucus-filled, along with buzzing or ringing in the ears, and possibly stomach cramps. Swallowing difficulties or pain, throat discomfort, acid reflux, a decrease in appetite, or chest pain that worsens while eating.
The global tularemia treatment market is segmented based on disease type, drugs, route of administration, distribution channel and region.
By the bacteria Francisella tularensis, which is prevalent throughout the northern hemisphere, tularemia, a rare zoonotic infection, is brought on. Through inoculation from the bites of arthropod vectors like ticks or stag flies, or by handling contaminated tissue from naturally occurring animal reservoirs like rabbits or small rodents, the ulceroglandular type of illness is spread.
Other types of exposure to polluted fluid or aerosol may cause systemic "typhoidal" disease, oropharyngeal disease, oculoglandular disease, or pneumonic disease. Intravenous aminoglycosides were once the standard of care, but recent research has shown that milder cases can be successfully treated with oral antibiotics such ciprofloxacin or tetracycline. With the rising population and growing geographical reach of its tick vectors, it is possible to expect an increase in the incidence of tularemia globally.
According to Illinois Department of Public Health, every year, the United States reports between 100 and 200 instances. Tularemia can result in six different disease types, although up to 80% of cases are "ulceroglandular" (characterized by skin ulcers and enlarged lymph nodes) and are brought on by close contact involving infected animals.
Due to the rising need for tularemia treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for tularemia treatment.
Increasing expenditure on healthcare, advancement of technologies and different treatment products for different tularemia disease types, along with increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of tularemia treatment market share of this region. The market in this area is growing as people become more aware of various novel treatments. The aforementioned elements attest to North America's hegemonic position in the world.
North America continues to be a key player in the global tularemia treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for antibiotics such as aminoglycosides in the United States which have been proactive in executing several initiatives or treatment, stimulating these drugs demand.
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global tularemia treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of fluoroquinolones or tetracyclines, was significantly impacted. The widespread lockdowns and restrictions imposed by the pandemic, which began in early 2020, had an effect on a number of initiatives all around the world.
Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for tularemia treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global tularemia treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel treatments.
The major global players in the market include: Pfizer Inc., Merck KGaA, Fujian Fukang Pharmaceutical Co., Ltd, Hikma Pharmaceuticals PLC, Cepham Life Sciences, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Midas Pharma GmbH, Camber Pharmaceuticals, Inc. and FUJIFILM Wako Pure Chemical Corporation.
The global tularemia treatment market report would provide approximately 69 tables, 70 figures and 186 Pages.
LIST NOT EXHAUSTIVE